Allogene Therapeutics - ALLO Stock Forecast, Price & News

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Allogene Therapeutics in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ALLO shares.
View ALLO analyst ratings or view top-rated stocks.

13 brokers have issued 1 year price targets for Allogene Therapeutics' stock. Their ALLO share price forecasts range from $6.00 to $31.00. On average, they expect the company's stock price to reach $17.69 in the next year. This suggests a possible upside of 251.7% from the stock's current price.
View analysts price targets for ALLO or view top-rated stocks among Wall Street analysts.

Allogene Therapeutics' stock was trading at $6.29 at the start of the year. Since then, ALLO shares have decreased by 20.0% and is now trading at $5.03.
View the best growth stocks for 2023 here.

Allogene Therapeutics saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 39,800,000 shares, an increase of 8.0% from the February 28th total of 36,860,000 shares. Based on an average daily trading volume, of 1,900,000 shares, the days-to-cover ratio is currently 20.9 days. Approximately 49.6% of the shares of the company are short sold.
View Allogene Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our ALLO earnings forecast.

Allogene Therapeutics, Inc. (NASDAQ:ALLO) posted its quarterly earnings data on Tuesday, February, 28th. The company reported ($0.66) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.71) by $0.05. The company earned $0.05 million during the quarter, compared to analyst estimates of $0.06 million. Allogene Therapeutics had a negative trailing twelve-month return on equity of 43.44% and a negative net margin of 136,885.59%. The firm's quarterly revenue was down 6.0% on a year-over-year basis. During the same period last year, the company earned ($0.54) earnings per share.

ETFs with the largest weight of Allogene Therapeutics (NASDAQ:ALLO) stock in their portfolio include Loncar Cancer Immunotherapy ETF (CNCR), Kelly CRISPR & Gene Editing Technology ETF (XDNA), iShares Genomics Immunology and Healthcare ETF (IDNA), Global X Genomics & Biotechnology ETF (GNOM), Virtus LifeSci Biotech Clinical Trials ETF (BBC), SPDR S&P Biotech ETF (XBI), WisdomTree BioRevolution Fund (WDNA) and Direxion Daily S&P Biotech Bull 3x Shares (LABU).

2 employees have rated Allogene Therapeutics Chief Executive Officer David Chang on Glassdoor.com. David Chang has an approval rating of 100% among the company's employees. This puts David Chang in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Allogene Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Pfizer (PFE), Teladoc Health (TDOC), AbbVie (ABBV), Alibaba Group (BABA), Bristol-Myers Squibb (BMY) and CRISPR Therapeutics (CRSP).

(ALLO) raised $272 million in an initial public offering on Thursday, October 11th 2018. The company issued 16,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Jefferies served as the underwriters for the IPO.

Allogene Therapeutics trades on the NASDAQ under the ticker symbol "ALLO."

Allogene Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (4.12%), JPMorgan Chase & Co. (2.61%), Millennium Management LLC (2.27%), Dimensional Fund Advisors LP (1.66%), Geode Capital Management LLC (1.18%) and Two Sigma Investments LP (1.12%). Insiders that own company stock include Alison Moore, Arie Belldegrun, David D Chang, Eric Thomas Schmidt, Group Holdings (Sbs) Advis Tpg, Owen N Witte, Owen N Witte, Rafael Amado and Veer Bhavnagri.
View institutional ownership trends.

Shares of ALLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ALLO stock can currently be purchased for approximately $5.03.

Allogene Therapeutics (NASDAQ:ALLO) has a market capitalization of $726.84 million and generates $240,000.00 in revenue each year. The company earns $-332,630,000.00 in net income (profit) each year or ($2.32) on an earnings per share basis.

The company employs 308 workers across the globe.

Allogene Therapeutics' mailing address is 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.allogene.com. The company can be reached via phone at (650) 457-2700 or via email at ir@allogene.com.